Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT03336528

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03336528
Other papers using this trial's data
  • Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes Diabetes, obesity & metabolism, 2022-01 DOI, PubMed 34490700, PMC8665002 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03336528. Randomized; no masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2021-03-01 (actual). Results posted on 2022-03-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
Intervention (Drug)
Degludec
Intervention (Drug)
Glargine
Intervention (Drug)
Aspart
Lead sponsor
Emory University (class: other)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03336528
Content hash
9f29476871c8cb176f570bd5ad17060968c8ba0ea4e5c61176e578eed7a17a60